A total of 378 novel drugs and 27 biosimilars approved by the US Food and Drug
Administration (FDA) between 2010 and 2019 were evaluated according to approval …

X‐linked hypophosphatemia (XLH) is the prototypic disorder of renal phosphate wasting,
and the most common form of heritable rickets. Physicians, patients, and support groups …

Context Younger age at treatment onset with conventional therapy (phosphate salts and
active vitamin D; Pi/D) is associated with improved growth and skeletal outcomes in children …

Phosphate plays essential roles in many biological processes, and the serum phosphate
level is tightly controlled. Chronic hypophosphatemia causes impaired mineralization of the …

A nationwide epidemiologic survey of fibroblast growth factor 23 (FGF23)-related
hypophosphatemic diseases was conducted in 2010 to clarify the prevalence and the …

Abstract Fibroblast growth factor 23 (FGF23) is a recently characterized protein likely
involved in the regulation of serum phosphate homeostasis. Increased circulating levels of …

Phosphate homeostasis is central to diverse physiologic processes including energy
homeostasis, formation of lipid bilayers, and bone formation. Reduced phosphate levels due …

Context: Treatment of X-linked hypophosphatemia (XLH) with active vitamin D metabolites
and phosphate can partially correct skeletal deformities. It is unclear whether therapy …

Abstract Burosumab (Crysvita®; Kyowa Hakko Kirin Co., Ltd. and Ultragenyx
Pharmaceutical Inc.) is a fully human monoclonal antibody directed at fibroblast growth …

PHEX is the gene defective in X-linked hypophosphatemic rickets. In this study, analysis of
PHEX revealed mutations in 22 hypophosphatemic rickets patients, including 16 of 28 …